Subicular degeneration occurs in amyotrophic lateral sclerosis (ALS) patients. However, it was unknown whether microscopic subicular degeneration could be observed as macroscopic changes and whether these changes were associated with the transactive-response DNA binding protein 43 kDa (TDP-43) pathology. Topographic differences between subicular degeneration caused by ALS and Alzheimer disease (AD) had also not been characterized. Here we investigated the subiculum and related areas in autopsied brains from 3 ALS and 3 AD patients. Macroscopic subicular thinning and corresponding astrocytosis were pronounced in ALS compared to AD. This thinning was frequently accompanied by TDP-43 pathology in the transentorhinal cortex and nucleus accumbens. The preferential susceptibility of the perforant pathway to TDP-43 deposition may be an underlying cause of subicular thinning in ALS.

Nakano I, Iwatsubo T, Hashizume Y, Mizutani T, Mannen T: Amyotrophic lateral sclerosis with dementia. Lesions in the apical cortex and some deeper structures of the temporal lobes. Neuropathology 1992; 12: 69–77.
Takeda T, Uchihara T, Mochizuki Y, Mizutani T, Iwata M: Memory deficits in amyotrophic lateral sclerosis patients with dementia and degeneration of the perforant pathway A clinicopathological study. J Neurol Sci 2007; 260: 225–230.
Takeda T, Uchihara T, Arai N, Mizutani T, Iwata M: Progression of hippocampal degeneration in amyotrophic lateral sclerosis with or without memory impairment: -distinction from Alzheimer disease. Acta Neuropathol 2009; 117: 35–44.
Abdulla S, Machts J, Kaufmann J, Patrick K, Kollewe K, Dengler R, et al: Hippocampal degeneration in patients with amyotrophic lateral sclerosis. Neurobiol Aging 2014; 35: 2639–2645.
Stoppel CM, Vielhaber S, Eckart C, Machts J, Kaufmann J, Heinze HJ, et al: Structural and functional hallmarks of amyotrophic lateral sclerosis progression in motor- and memory-related brain regions. Neuroimage Clin 2014; 5: 277–290.
Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239–259.
Turner MR, Verstraete E: What does imaging reveal about the pathology of amyotrophic lateral sclerosis? Curr Neurol Neurosci Rep 2015; 15: 45.
Inukai Y, Nonaka T, Arai T, Yoshida M, Hashizume Y, Beach TG, et al: Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLD-U and ALS. FEBS Lett 2008; 582: 2899–2904.
Biernat J, Mandelkow EM, Schröter C, Lichtenberg-Kraag B, Steiner B, Berling B, et al: The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J 1992; 11: 1593–1597.
Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E, et al: A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 2011; 122: 111–113.
Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M, et al: Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 2013; 74: 20–38.
Witter MP, Amaral DG: Entorhinal cortex of the monkey: V. Projections to the dentate gyrus, hippocampus, and subicular complex. J Comp Neurol 1991; 307: 437–459.
Ishizuka N: Laminar organization of the pyramidal cell layer of the subiculum in the rat. J Comp Neurol 2001; 435: 89–110
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.